C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Techno Trends

TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.

Novel Avacincaptad Pegol Developed for Geographic Atrophy

IVERIC bio, Inc developed avacincaptad pegol to treat geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitorhave shown positive results from the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal...

Pfizer Developed Elranatamab for Relapsed or Refractory Multiple Myeloma

Pfizer Inc, developed investigational elranatamab a cancer immunotherapy for the treatment of indivuduals with relapsed or refractory multiple myeloma (RRMM). Elranatamab is bindedwith B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), present on the surface of multiple myeloma (MM) cells, and the CD3 receptor found...

First-of-its-Kind Setmelanotide Discovered for Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc discovers first-of-its-kind setmelanotide for the treatment of obesity. Setmelanotide is not indicated for treating patients with suspected obesity due to POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign. It is also not indicated for obesity related...

Novel Ivonescimab (PD-1/VEGF Bispecific Antibody Developed for Non-Small-Cell Lung Carcinoma (NSCLC) patients

Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients. Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1...

Breakthrough CMG901 Drug Introduced for Advanced Gastric Cancer

Connoya introduced CMG901, novel drug for the treatment of Claudin 18.2-positive advanced gastric cancer. This new drug is indicated after first-line or treatment failure or intolerance. CMG901 previously granted orphan drug designation and fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory gastric cancer...

Novel Retevmo® (selpercatinib) Developed for Advanced or Metastatic Solid Tumors

Eli Lilly and Company developed novel Retevmo® (selpercatinib, 40 mg & 80 mg capsules) for the treatment of Advanced or Metastatic Solid Tumors in adults. Retevmo is the novel and only approved RET inhibitor to receive both tumor-agnostic accelerated approval and traditional approval in NSCLC, thus providing meaningful clinical...

Novel SirPlux Duo Drug-Coated Balloon Discovered for Small Vessel Coronary Artery Disease

Advanced NanoTherapies, Inc discovered novel SirPlux Duo Drug-Coated Balloon (DCB) for the treatment of small vessel coronary artery disease less than 3.0mm. The discovery of novel SirPlux Duo Drug-Coated Balloon (DCB) becomes a stent-free option to fill this clinical gap. Although having various advancement in drug-eluting stents...

First of its Kind IMBRUVICA® (ibrutinib) Developed for the Treatment of Chronic Graft-Versus-Host Disease (cGVHD)

The Janssen Pharmaceutical Companies of Johnson & Johnson developed IMBRUVICA® (ibrutinib) the first and only treatment for Chronic Graft-Versus-Host Disease in pediatric patients. IMBRUVICA® is the only BTKi treatment approved by FDA applicable for individuals with one year and older with chronic graft-versus-host disease (cGVHD) regardless of one or more systemic therapy failures....

Auvelity™, Novel Treatment Discovered for the Treatment of Depressive Disorder

Axsome Therapeutics, Inc discovers novel AUVELITYTM (dextromethorphan HBr -bupropion HCl) extended release tablets for the treatment of major depressive disorders in adults. It is the novel oral NMDA receptor antagonist consisting of multimodal activity approved for the treatment of MDD in adults....

Breakthrough Taletrectinib Developed for Non-Small Cell Lung Cancer

AnHeart Therapeutics discovered breakthrough investigational ROS-1 inhibitor taletrectinib for the treatment of patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Taletrectinib is applicable for patients with ROS1 tyrosine kinase inhibitor...

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA SGS - ADVANCED ANALYTICS Adare Pharma Solutions - Pediatric Formulation Solutions Thermo Fisher Scientific - LC-MS biopharmaceutical applications CPHI PMEC China - Virtual Expo Connect ThermoFisher - Accekerate therapeutic development